62516-08-9

Basic information

• Product Name: PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE
• Synonyms: PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE;5-Bromo-2-methyl-4-nitropyridine N-oxide;4-nitro-5-broMo-2-picoline N-oxide;5-broMo-2-Methyl-4-nitropyridine 1-oxide;5-BroMo-2-Methyl-4-nitrop...;4-nitro-5-broMo-2-picoline;5-bromo-2-methyl-4-nitro-1-oxidopyridin-1-ium
• CAS NO: 62516-08-9
• Molecular Formula: C₆H₅BrN₂O₃
• Molecular Weight: 233.02
• EINECS: 200-589-5
• Product Categories: alkyl bromide|nitro-compound
• Mol File: 62516-08-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE(62516-08-9)
• EPA Substance Registry System: PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE(62516-08-9)

Safety Data

• Hazardous Substances Data: 62516-08-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE is employed as a key intermediate in the development of new drugs. Its structural features enable it to be a potential candidate for the treatment of various diseases, including cancer.
Used in Anti-Cancer Applications:
PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE has been studied for its potential as an anti-cancer agent. Its unique chemical properties allow it to interact with biological targets, such as enzymes and receptors, involved in the regulation of cell growth and proliferation. This makes it a promising candidate for the development of novel therapeutic agents against cancer.
Used as a Precursor in Medicinal Chemistry:
PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE also serves as a precursor in the synthesis of other compounds with medicinal properties. Its reactivity and functional groups make it an ideal starting material for the preparation of bioactive molecules with potential therapeutic applications.
However, it is important to note that PYRIDINE, 5-BROMO-2-METHYL-4-NITRO-, 1-OXIDE has irritating effects on the skin, eyes, and respiratory system. Therefore, it should be handled with caution in laboratory and industrial settings to ensure the safety of workers and the environment.

Upstream product

• 31181-64-3 5-bromo-2-methyl-pyridine-N-oxide 
• 3430-13-5 5-bromo-2-methylpyridine 

Downstream Products

• 1070972-66-5 4-chloro-5-(4-chloro-6-methyl-pyridin-3-yl)-2-fluoro-N-(2-methoxy-phenyl)-N-methyl-benzenesulfonamide 
• 1003711-85-0 5-bromo-4-chloro-2-methylpyridine 
• 1260162-97-7 N-[5-(3-chlorophenyl)-2-methylpyridin-4-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1060802-25-6 5-bromo-4-chloropicolinic acid 
• 1260162-47-7 N-(5-(2,5-dichlorophenyl)-2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 122307-33-9 (5-bromo-4-methoxypyridin-2-yl)methanol 
• 103971-44-4 4-chloro-5-bromo-2-hydroxymethylpyridine 
• 108004-86-0 5-bromo-4-methoxy-2-picoline N-oxide 

Relevant articles and documents

DO3A type highly stable paramagnetic probe capable of being used for intracellular magnetic resonance research and preparation method of DO3A type highly stable paramagnetic probe

The invention provides a DO3A type highly stable paramagnetic probe T1 capable of being used for intracellular magnetic resonance research and a preparation method of the DO3A type highly stable paramagnetic probe T1. The structural formula of the paramag

A Reactive, Rigid GdIII Labeling Tag for In-Cell EPR Distance Measurements in Proteins

The cellular environment of proteins differs considerably from in vitro conditions under which most studies of protein structures are carried out. Therefore, there is a growing interest in determining dynamics and structures of proteins in the cell. A key factor for in-cell distance measurements by the double electron–electron resonance (DEER) method in proteins is the nature of the used spin label. Here we present a newly designed GdIII spin label, a thiol-specific DOTA-derivative (DO3MA-3BrPy), which features chemical stability and kinetic inertness, high efficiency in protein labelling, a short rigid tether, as well as favorable spectroscopic properties, all are particularly suitable for in-cell distance measurements by the DEER method carried out at W-band frequencies. The high performance of DO3MA-3BrPy-GdIII is demonstrated on doubly labelled ubiquitin D39C/E64C, both in vitro and in HeLa cells. High-quality DEER data could be obtained in HeLa cells up to 12 h after protein delivery at in-cell protein concentrations as low as 5–10 μm.

INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF

The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as i

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors

The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the p

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical

INHIBITORS OF AKT ACTIVITY

Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

MCH receptor antagonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.